Solid Biosciences (SLDB) Enterprise Value (2017 - 2024)
Solid Biosciences (SLDB) has disclosed Enterprise Value for 8 consecutive years, with -$171.1 million as the latest value for Q3 2024.
- Quarterly Enterprise Value fell 19.76% to -$171.1 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was -$171.1 million through Sep 2024, down 19.76% year-over-year, with the annual reading at -$123.6 million for FY2023, 42.15% up from the prior year.
- Enterprise Value hit -$171.1 million in Q3 2024 for Solid Biosciences, up from -$190.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$24.8 million in Q3 2020 to a low of -$268.5 million in Q1 2021.
- Historically, Enterprise Value has averaged -$149.0 million across 5 years, with a median of -$160.2 million in 2023.
- Biggest five-year swings in Enterprise Value: surged 76.6% in 2020 and later tumbled 398.01% in 2021.
- Year by year, Enterprise Value stood at -$155.1 million in 2020, then plummeted by 33.99% to -$207.8 million in 2021, then fell by 2.86% to -$213.7 million in 2022, then surged by 42.15% to -$123.6 million in 2023, then plummeted by 38.4% to -$171.1 million in 2024.
- Business Quant data shows Enterprise Value for SLDB at -$171.1 million in Q3 2024, -$190.3 million in Q2 2024, and -$206.1 million in Q1 2024.